IMR Press / FBL / Volume 10 / Issue 2 / DOI: 10.2741/1668

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

New anti-cancer strategies: epigenetic therapies and biomarkers
Show Less
1 Medical Sciences, Indiana University, Bloomington, IN 47405, USA
2 School of Informatics, Indiana University, Bloomington, IN, 47408
3 Center for Genomics and Bioinformatics, Indiana University, Bloomington, IN, 47405
4 Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210
5 Indiana University Cancer Center, Indianapolis, IN, 46202
Front. Biosci. (Landmark Ed) 2005, 10(2), 1897–1931;
Published: 1 May 2005

Epigenetics is the study of chromatin modifications that affect gene expression without altering DNA nucleotide sequences. This review highlights a prominent role for epigenetic therapies, particularly those that reverse aberrant DNA methylation and histone acetylation, in the potential treatment of cancer. Administration of such therapies to reverse epigenetic "silencing" of tumor suppressors, including genes involved in chemotherapy responses, could prove useful in the management of cancer patients. In this review, we summarize recent advances in the use of methyltransferase and histone deacetylase inhibitors and possible synergistic combinations of these to achieve maximal tumor suppressor gene re-expression. Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize drug-resistant tumors to established treatments. As specific, aberrant epigenetic modifications are frequently associated with distinct cancer types, and likely occur early in tumorigenesis, these have potential utility as biomarkers. Finally, future directions are addressed, including alternative epigenetic targets, gene-specific modifications, and the use of bioinformatics.

DNA Methylation
Drug Resistance
Epigenetic Biomarkers
Epigenetic Therapies
HDAC Inhibitor
Histone Deacetylase
Methylation Biomarkers
Back to top